Moderate Evidence
Research Overview
Pemvidutide Research for Obesity
An evidence-based overview of research examining Pemvidutide in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
Phase 2b MOMENTUM trial demonstrated 15.6% weight loss at 48 weeks with 2.4mg dose. Weight loss trajectory had not plateaued, suggesting continued benefit with longer treatment. 78% of weight lost was fat mass, superior to GLP-1-only agents.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.